🧪📈 Sai Life Sciences Delivers Strong FY26 Performance with 29% Revenue Growth & 109% Jump in Profit

Sai Life Sciences reported a strong set of FY26 results, reflecting robust growth across its CRDMO business and continued momentum in global pharma partnerships. 🚀 💰 Revenue from operations for FY26 increased 29% YoY to ₹2,192 crore, compared to ₹1,695 crore in FY25, driven by deeper engagement with large pharmaceutical clients and continued growth in integrated discovery services. 📊 EBITDA surged 56% YoY to ₹661 crore, with EBITDA margins improving to 30%, showcasing stronger operational efficiency and scalability. Meanwhile, Profit After Tax (PAT) more than doubled, rising 109% YoY to ₹355 crore—a significant milestone for the company. 🔬 The company highlighted continued investments in new modalities and next-generation technologies, along with a capital expenditure of ₹633 crore to support future expansion and strengthen capabilities. 🌍 Management remains optimistic about the long-term opportunity in innovation-led outsourcing and supply chain diversification, positioning the company well for the next phase of growth. With improving margins, accelerating profitability, and strategic investments in advanced capabilities, Sai Life Sciences continues to strengthen its position as one of India’s fastest-growing CRDMO players. 🔥 ⚠️ Disclaimer: This post is for educational and informational purposes only and should not be considered investment advice. Investments in securities markets are subject to market risks. 👍 Like • 🔁 Share • ➕ Follow for more market and earnings updates